428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries

Background

A breast cancer risk assessment tool, utilizing a polygenic risk score based on 313 single nucleotide polymorphisms and a risk prediction algorithm from the Gail Model, has been established and validated for the Asian population. Facilitated focus group discussions were conducted to assess the preferences of women from two Asian countries regarding the presentation of risk results, the level of detail provided for explanations, and recommendations for follow-up actions.

Methods

This qualitative study took place from July to October 2022 to evaluate the perspectives of women in Indonesia and Singapore regarding personalized breast cancer risk assessment. Participants were presented with either a detailed high-risk or low-risk mock report and were then assigned to high-risk or low-risk result focus groups based on the report they received randomly. Thematic analysis was performed on the content of all focus group discussions.

Results

The majority of participants emphasized the importance of using non-intimidating visuals and incorporating a summary on the first page of the report to facilitate interpretation. Participants also recommended the use of simplified language to enhance communication styles. Notably, participants who received high-risk results reported feeling anxious, while those with low-risk results expressed relief. Overall, participants found the report valuable and expressed interest in similar reports covering other diseases in the future.

Conclusions

In conclusion, the study reveals that most patients prefer test reports that strike a balance between content and complexity. It highlights the psychological impact on patients receiving test results, which is greatly influenced by their level of understanding and interpretation of the reports. Additionally, the study suggests that increased patient engagement with physicians is likely following the receipt of test results. As a result, future research could be extended to include physicians directly involved in the delivery of breast cancer prevention care.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Nalagenetics Pte Ltd.

Disclosure

All authors have declared no conflicts of interest.